Active substanceFluconazoleFluconazole
Similar drugsTo uncover
  • Vero-Fluconazole
    capsules inwards 
    VEROPHARM SA     Russia
  • Disorel-Sanovel
    capsules inwards 
  • Diflazon®
    solution d / infusion 
  • Diflucan®
    powder inwards 
    Pfizer Inc.     USA
  • Diflucan®
    capsules inwards 
    Pfizer Inc.     USA
  • Diflucan®
    solution in / in 
    Pfizer Inc.     USA
  • Micon
    solution d / infusion 
  • Medoflucon®
    capsules inwards 
    MEDSERV, LLC     Russia
  • Mycomomax®
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Mycosyst®
    capsules inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Mycosyst®
    solution d / infusion 
    GEDEON RICHTER, OJSC     Hungary
  • Mycoflucan®
    pills inwards 
  • Mycoflucan®
    solution d / infusion 
  • Nofung®
    capsules inwards 
  • Procanazole
    capsules inwards 
  • Fangifflu
    capsules inwards 
  • Flukozan
    solution d / infusion 
    LENS-PHARM, LLC     Russia
  • Flukoside
    capsules inwards 
  • Flukomabol®
    solution d / infusion 
    PREBAND PFC, LLC     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    PHARMACY 36.6, CJSC     Russia
  • Fluconazole
    solution d / infusion 
  • Fluconazole
    capsules inwards 
  • Fluconazole
    solution d / infusion 
    RUSYUROFARM, LLC     Russia
  • Fluconazole
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Fluconazole
    capsules inwards 
    REPLEK FARM Skopje, OOO     Macedonia
  • Fluconazole
    capsules inwards 
    FARMPROJECT, CJSC     Russia
  • Fluconazole
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    OZONE, LLC     Russia
  • Fluconazole
    capsules inwards 
    BIOKOM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    VERTEKS, AO     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    pills inwards 
    TECHNOLOG, JSC     Ukraine
  • Fluconazole
    capsules inwards 
    Hemofarm AD     Serbia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    Astrafarm, CJSC     Russia
  • Fluconazole
    capsules inwards 
    MEDISORB, CJSC     Russia
  • Fluconazole OBL
    capsules inwards 
  • Fluconazole Zentiva
    solution d / infusion 
    Zentiva c.s.     Czech Republic
  • Fluconazole Cabi
    solution d / infusion 
  • Fluconazole STADA
    capsules inwards 
  • Fluconazole-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
  • Fluconazole-Sandoz®
    capsules inwards 
    Sandoz d.     Slovenia
  • Fluconazole-Teva
    capsules inwards 
  • Flukonorm
    capsules inwards 
  • Flucorus®
    solution d / infusion 
    MS-VITA, LLC     Russia
  • Flukorem
    gel externally 
    REMEDIYA, LLC     Russia
  • Flucostat®
    solution d / infusion 
  • Flucostat®
    capsules inwards 
  • Forkan®
    solution d / infusion 
    Cipla Ltd.     India
  • Forkan®
    capsules inwards 
    Cipla Ltd.     India
  • Ciscan®
    capsules inwards 
  • Dosage form: & nbspcapsules
    Composition:

    in one capsule

    Active substance: fluconazole 50 mg or 150 mg.

    Excipients: microcrystalline cellulose, sodium lauryl sulfate, sodium carboxymethyl starch, colloidal silicon dioxide.

    The composition of the capsule shell is gelatin capsules # 4, Ns.1 unprintable:

    Body: titanium dioxide, methyl parahydroxybenzoate, propyl parahydroxybenzoate. Cover: titanium dioxide, dyes: indigo carmine, quinoline yellow.

    Description:

    Capsules of 50 mg:

    Hard gelatin capsules No. 4 with a white casing and a blue lid containing a white powder.

    Capsules of 150 mg:

    Hard gelatin capsules No. 1, with a white casing and a blue lid containing a white powder.

    Pharmacotherapeutic group:Antifungal agent.
    ATX: & nbsp

    J.02.A.C   Triazole derivatives

    J.02.A.C.01   Fluconazole

    Pharmacodynamics:

    Fluconazole, a representative of the class of triazole antifungal agents, is a potent selective inhibitor of the synthesis of sterols in the fungal cell.

    The drug is effective in opportunistic fungal infections, incl. caused by Candida spp., Cryptococcus neoformans, Microsporum spp., Trichophyton spp. Also shown is the activity of fluconazole in endemic mycosis models, including infections caused by Blastomyces dermatitidis, Coccidiodes immitis and Histoplasma capsulatum.

    Pharmacokinetics:

    After oral administration fluconazole it is well absorbed, its bioavailability is 90%. The maximum concentration after ingestion, fasting 150 mg is 90% of the plasma content when administered intravenously at a dose of 2.5 - 3.5 mg / l.Simultaneous food intake does not affect the absorption of the drug taken internally. The concentration in the plasma reaches a peak after 0.5-1.5 hours after administration, the half-life of fluconazole is about 30 hours. The plasma concentrations are in direct proportion to the dose. 90% equilibrium level concentration is achieved by 4-5 days of treatment with the drug (when taken 1 time / day).

    The introduction of a shock dose (on the first day), 2 times higher than the usual daily dose, makes it possible to achieve a level corresponding to 90% -equilibrium. concentration, by the second day. The apparent volume of distribution approximates the total water content in the body. Binding to plasma proteins - 11-12%.

    Fluconazole well penetrates into all biological fluids in the body.

    Concentrations of the drug in saliva and sputum are similar to those in plasma. In patients with fungal meningitis, the fluconazole content in the cerebrospinal fluid reaches 80% of its plasma level.

    In the stratum corneum, the epidermis, the dermis and the sweat fluid, high concentrations are reached that exceed the serum levels.

    Fluconazole is mainly caused by the kidneys; approximately 80% of the administered dose is excreted in the urine unchanged.The clearance of fluconazole is proportional to the creatinine clearance. Metabolites of fluconazole in peripheral blood not detected

    Indications:

    -cryptococcosis, including cryptococcal meningitis and other localizations of this infection (including lungs, skin), both in patients with normal immune response, and in patients with various forms of immunosuppression (including, in patients with AIDS, organ transplantation); the drug can be used to prevent cryptococcal infection in AIDS patients;

    -generative candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis infections (peritoneal, endocardial, eye, respiratory and urinary tract infections). Treatment can be carried out in patients with malignant neoplasms, in intensive care units, in patients undergoing dystostatic or kmunosupressive therapy, and in the presence of other factors predisposing to the development of candidiasis;

    -candidosis of mucous membranes, incl. oral cavity and pharynx (including atrophic candidiasis of the oral cavity, associated with the wearing of dentures), esophagus, non-invasive bronchopulmonary candidiasis, candiduria,candidiasis of the skin; prevention of recurrence of oropharyngeal candidiasis in AIDS patients;

    -genital candidiasis: vaginal candidiasis (acute and chronic

    relapsing), prophylactic use to reduce the frequency of recurrences of vaginal candidiasis (3 or more episodes per year); Candidiasis balanitis;

    -prophylaxis of fungal infections in patients with malignant neoplasms that are predisposed to such infections as a result of chemotherapy with cytostatics or radiation therapy;

    - mikozy skin, including mycosis of the feet, body, inguinal area; pityriasis shingles, onychomycosis; candidiasis of the skin;

    - Deep endemic mycoses, including coccidiomycosis, paracoccidiomycosis, sporotrichosis and histoplasmosis in patients with normal-immunity

    Contraindications:

    - simultaneous reception of terfenadine or astemizole and other drugs that extend the interval QT.

    -increased sensitivity to the drug or similar in structure to azole compounds.

    -Children under 3 years old.

    Carefully:

    Hepatic and / or renal failure, concurrent administration of potentially 'heterocytotoxic drugs,' alcoholism, potentially proaritogenic condition in patients with multiple risk factors (organic heart disease, electrolyte balance disorders, simultaneous intake of drugs that cause arrhythmias).

    Pregnancy and lactation:

    -The use of the drug in pregnant women is inappropriate, except for heavy

    or life-threatening forms of fungal infections if the intended effect exceeds the possible risk to the fetus.

    Fluconazole is in breast milk in the same amount as in plasma because its purpose during lactation is not recommended.

    Dosing and Administration:

    Inside. Adults at Cryptococcal meningitis and cryptococcal infections of other sites on the first day 400 mg (8 capsules to 50 mg) are usually prescribed, and then continue treatment at a dose of 200-400 mg (4-8 capsules to 50 mg) 1 time / day. The duration of treatment for cryptococcal infections depends on the clinical efficacy, confirmed by mycological examination; in cryptococcal meningitis, it is usually continued for at least 6-8 weeks.

    For prevention of recurrence of cryptococcal meningitis in patients with AIDS after completion of the full course of primary treatment fluconazole prescribe a dose of 200 mg (4 capsules to 50 mg) per day for a long period of time.

    When candidemia, disseminated candidiasis and other invasive candidiasis infections The dose is usually 400 mg (8 capsules to 50 mg) on ​​the first day, and then to 200 mg (4 capsules to 50 mg). With insufficient clinical effectiveness, the dose of the drug can be increased to 400 mg / day. The duration of therapy depends on clinical effectiveness.

    When oropharyngeal candidiasis the drug is usually prescribed for 150 mg 1 time / day; the duration of treatment is 7-14 days. If necessary, in patients with a marked decrease in immunity, treatment may be longer.

    When other localizations of candidiasis (with the exception of genital candidiasis), for example, with esophagitis, non-invasive bronchopulmonary disease, candiduria, candidiasis of the skin and mucous membranes, etc., the effective dose is usually 150 mg / day with a treatment duration of 14-30 days. For prevention relapses of oropharyngeal candidiasis in patients with AIDS after the completion of a full course of primary therapy, the drug can be administered at 150 mg once a week.

    When vaginal candidiasis fluconazole taken once inside the dose of 150 mg. For decrease in the frequency of recurrences of vaginal candidiasis the drug can be used in a dose of 150 mg once a month. The duration of therapy is determined individually; it varies from 4 to 12 months. Some patients may need more frequent use.

    When balanitis caused by Candida, fluconazole appoint a single dose of 150 mg orally.

    For prevention of candidiasis the recommended dose of fluconazole is 150-400 mg 1 time / day, depending on the degree of risk of fungal infection. If there is a high risk of generalized infection, for example, in patients with expected severe or persistent neutropenia, the recommended dose is 400 mg (8 capsules 50 mg) 1 time / day. Fluconazole appoint a few days before the expected appearance of neutropenia; after an increase in the number of neutrophils more than 1000 / mm3 treatment is continued for another 7 days.

    When mycosis of the skin, including mycosis of the feet, skin of the inguinal region and skin candidiasisthe recommended dose is 150 mg once a week. Duration of therapy in usual cases is 2-4 weeks, however, with foot mycoses, longer therapy (up to 6 weeks) may be required.

    When pityriasis 300 mg (2 caps.150 mg) once a week for 2 weeks, some patients require a third dose of 300 mg per week, while in some cases it is sufficient to receive 300-400 mg once a day.

    With onichomycosis the recommended dose is 150 mg once a week, treatment should continue until the replacement of the infected nail (nonsinfected nail growth). To completely replace the nails on the fingers and toes, it normally takes 3-6 months and 6-12 months, respectively.

    When deep endemic mycoses may require the use of the drug at a dose of 200 -400 mg / day for up to 2 years. The duration of therapy is determined individually; it can be 11-24 months with coccidioidomycosis; 2-17 months with paracoccidioidomycosis; 1-16 months with sporotrichosis and 3-17 months with histoplasmosis.

    Have children, as with similar infections in adults, the duration of treatment depends on the clinical and mycological effect. In children, the drug should not be used in a daily dose that would exceed that of adults. The drug is used daily 1 time / day.

    When candidiasis of mucous membranes the recommended dose of fluconazole is 3 mg / kg / day. On the first day, a shock dose of 6 mg / kg can be given to achieve a faster Cssmax.

    For treatment of generalized candidiasis or cryptococcal infectionthe recommended dose is 6-12 mg / kg / day, depending on the severity of the disease.

    For prevention of fungal infections the children with reduced immunity, at which the risk of infection is associated with neutropenia, resulting from cytotoxic chemotherapy or radiation therapy, the drug is prescribed at 3-12 mg / kg / day, depending on the severity and duration of preservation of induced neutropenia.

    Have children with impaired renal function the daily dose of the drug should be reduced (in the same proportional relationship as in adults), in accordance with the degree of renal insufficiency.

    Have elderly patients in the absence of violations of kidney function should follow the usual dosage regimen. Patients with renal insufficiency (CC <50 ml / min) dosage regimen should be adjusted, as indicated below.

    Use of the drug in patients with impaired renal function:

    Fluconazole is excreted mainly by the kidneys in unchanged form. With a single admission, a dose change is not required.When re-administering the drug, patients with impaired renal function should first inject a shock dose of up to 400 mg. If the creatinine clearance (CK) is more than 50 ml / min, the usual dose of the drug (100% of the recommended dose) is used. With SC from 11 to 50 ml / min, a dose equal to 50% of the recommended dose is applied. Patients regularly on dialysis, one dose of the drug is used after each session of hemodialysis.

    Side effects:

    From the digestive system: changes in taste, vomiting, nausea, diarrhea, flatulence, abdominal pain, rarely - impaired liver function (jaundice, hepatitis, hepatonecrosis, hyperbilirubinemia, increased activity of alanine aminotransferases, aspartate aminotransferase, increased alkaline phosphatase activity), incl. heavy.

    From the side of the central nervous system: headache, dizziness, rarely - convulsions.

    From the hematopoiesis: rarely - leukopenia, thrombocytopenia, neutropenia, agranulocytosis.

    From the cardiovascular system: increase in the duration of the QT interval, fibrillation / flutter of the ventricles.

    Allergic reactions: skin rash, rarely - malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), anaphylactoid reactions.

    Other: rarely - renal dysfunction, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

    Overdose:

    Treatment: symptomatic, gastric lavage, forced diuresis Hemodialysis for 3 hours reduces the plasma concentration by about 50%.

    Interaction:

    When using fluconazole with warfarin, prothrombin time increases (on average by 12%). In this regard, it is recommended to carefully monitor the prothrombin time in patients receiving the drug in combination with coumarin anticoagulants.

    Fluconazole increases T1/2 from the plasma of oral hypoglycemic agents - derivatives of sulfonylureas (chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy people. Joint use of fluconazole and oral hypoglycemic agents in diabetic patients is allowed, but the doctor should keep in mind the possibility of developing hypoglycemia.

    The simultaneous use of fluconazole and phenytoin can lead to an increase in the concentration of phenytoin in the plasma to a clinically significant degree. Therefore, when it is necessary to jointly use these drugs, it is necessary to monitor the concentrations of phenytoin with correction of its dose in order to maintain the drug level within the therapeutic interval.

    The combination with rifampicin results in a 25% reduction in AUC and a shortening of T1/2fluconazole from plasma by 20%. Therefore, patients receiving concomitantly rifampicin, it is advisable to increase the dose of fluconazole.

    It is recommended to monitor the concentration of cyclosporine in the blood in patients receiving fluconazole, since the use of fluconazole and cyclosporine in patients with kidney transplantation of fluconazole at a dose of 200 mg / day leads to a slow increase in the concentration of cyclosporine in the plasma.

    Patients who receive high doses of theophylline, or who are likely to develop theophylline intoxication, should be monitored for the early detection of symptoms of theophylline overdose, as taking fluconazole leads to a decrease in the average clearance rate of theophylline from the plasma.

    With the simultaneous use of fluconazole and terfenadine, cisapride, cases of unwanted reactions from the heart, including paroxysms of ventricular tachycardia (torsades de points), are described.

    Simultaneous use of fluconazole and hydrochlorothiazide can lead to an increase in the concentration of fluconazole in plasma by 40%.

    There have been reports of an interaction between fluconazole and rifabutin, accompanied by an increase in the serum levels of the latter. With the simultaneous use of fluconazole and rifabutin, cases of uveitis are described. It is necessary to carefully observe patients who simultaneously receive rifabutin and fluconazole.

    In patients receiving a combination of fluconazole and zidovudine, an increase in the concentration of zidovudine is observed, which is caused by a decrease in the conversion of the latter into its main metabolite, so the side effects of zidovudine should be expected to increase.

    Increases the concentration of midazolam, which increases the risk of developing psychomotor effects (most pronounced when fluconazole is administered orally than intravenously).

    Increases the concentration of tacrolimus, in connection with which the risk of nephrotoxic action increases.

    Special instructions:

    Treatment should continue until the appearance of clinical-hematologic remission. Premature termination of treatment leads to relapse.


    In rare cases, the use of flucocosol was accompanied by toxic changes in the liver, including. with a fatal outcome, mainly in patients with serious concomitant diseases.In the case of hepatotoxic effects associated with fluconazole, there was no apparent dependence on the total daily dose, duration of therapy, sex, and age of the patient. The hepatotoxic effect of schluconazole was usually reversible; signs of it disappeared after discontinuation of therapy. When there are clinical signs of liver damage, which nodes are associated with fluconazole, the drug should be discarded.

    Patients with AIDS are more likely to develop severe skin reactions with many drugs. In those cases when patients with superficial fungal infection develops a rash and it is regarded as definitely associated with fluconazole, the drug should be discarded. When rashes appear in patients with invasive / systemic fungal infections, they should be carefully monitored and canceled fluconazole when there are bullous changes or erythema multiforme.

    Caution should be exercised while taking fluconazole with cisapride, rifabutin or other drugs metabolized by the cytochrome P 450 system.

    Form release / dosage:Capsules of 50 mg and 150 mg
    Packaging:

    For 7 capsules in a blister of PVC Ulyumiyayevoy ,.one blister with instructions for use in a cardboard pack.

    One capsule per blister is made of PVC / aluminum, one blister together with the instruction but application in a cardboard pack.

    Storage conditions:

    In a dry, dark place at a temperature of not more than 25 "C.

    Keep out of the reach of children.


    Shelf life:

    3 years. Do not use after expiry date. Conditions for leaving pharmacies

    Terms of leave from pharmacies:On prescription
    Registration number:12.03.2012
    Date of registration:LS-002114
    The owner of the registration certificate:Roushan Pharma Co., Ltd.Roushan Pharma Co., Ltd. India
    Manufacturer: & nbsp
    Information update date: & nbsp26.09.2015
    Illustrated instructions
      Instructions
      Up